Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems.
Pyridine derivatives with one or more keto groups on the ring.
Therapy of heavy metal poisoning using agents which sequester the metal from organs or tissues and bind it firmly within the ring structure of a new compound which can be eliminated from the body.
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.
A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN.
Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994)
A form of pneumoconiosis resulting from inhalation of iron in the mining dust or welding fumes.
Agents counteracting or neutralizing the action of POISONS.
Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure.
Inorganic compounds that contain the OH- group.
Highly reactive molecules with an unsatisfied electron valence pair. Free radicals are produced in both normal and pathological processes. They are proven or suspected agents of tissue damage in a wide variety of circumstances including radiation, damage from environment chemicals, and aging. Natural and pharmacological prevention of free radical damage is being actively investigated.
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.
Conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the MONONUCLEAR PHAGOCYTE SYSTEM, without demonstrable tissue damage. The name refers to the presence of stainable iron in the tissue in the form of hemosiderin.
Bleeding into one or both CEREBRAL HEMISPHERES due to TRAUMA. Hemorrhage may involve any part of the CEREBRAL CORTEX and the BASAL GANGLIA. Depending on the severity of bleeding, clinical features may include SEIZURES; APHASIA; VISION DISORDERS; MOVEMENT DISORDERS; PARALYSIS; and COMA.
A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials.
Unstable isotopes of iron that decay or disintegrate emitting radiation. Fe atoms with atomic weights 52, 53, 55, and 59-61 are radioactive iron isotopes.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
A complex of ferric oxyhydroxide with dextrans of 5000 to 7000 daltons in a viscous solution containing 50 mg/ml of iron. It is supplied as a parenteral preparation and is used as a hematinic. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1292)
An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.
Substances that influence the course of a chemical reaction by ready combination with free radicals. Among other effects, this combining activity protects pancreatic islets against damage by cytokines and prevents myocardial and pulmonary perfusion injuries.
Starches that have been chemically modified so that a percentage of OH groups are substituted with 2-hydroxyethyl ether groups.
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.
Procedures concerned with the remedial treatment or prevention of diseases.
A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.
Foodstuff used especially for domestic and laboratory animals, or livestock.
3-Hydroxy-4-oxo-1(4H)-pyridinealanine. An antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca.
Membrane glycoproteins found in high concentrations on iron-utilizing cells. They specifically bind iron-bearing transferrin, are endocytosed with its ligand and then returned to the cell surface where transferrin without its iron is released.
A reagent used for the determination of iron.
Privately endowed or public charities or institutions receiving and supporting the aged or infirm poor. They sometimes functioned as centers of health care before the establishment of formal hospitals. (From Random House Unabridged Dictionary, 2d ed & Dr. James H. Cassedy, NLM History of Medicine Division)
Electron-accepting molecules in chemical reactions in which electrons are transferred from one molecule to another (OXIDATION-REDUCTION).
Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of signal transduction and gene expression, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS.
Inorganic or organic compounds that contain divalent iron.
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Agencies of the FEDERAL GOVERNMENT of the United States.
A 34-amino acid polypeptide antibiotic produced by Streptococcus lactis. It has been used as a food preservative in canned fruits and vegetables, and cheese.
The process of discovering or asserting an objective or intrinsic relation between two objects or concepts; a faculty or power that enables a person to make judgments; the process of bringing to light and asserting the implicit meaning of a concept; a critical evaluation of a person or situation.
A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy.
An operating division of the US Department of Health and Human Services. It is concerned with the overall planning, promoting, and administering of programs pertaining to health and medical research. Until 1995, it was an agency of the United States PUBLIC HEALTH SERVICE.
The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
The absence of a useful purpose or useful result in a diagnostic procedure or therapeutic intervention. The situation of a patient whose condition will not be improved by treatment or instances in which treatment preserves permanent unconsciousness or cannot end dependence on intensive medical care. (From Ann Intern Med 1990 Jun 15;112(12):949)
The state of the ATMOSPHERE over minutes to months.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
The conjugation of exogenous substances with various hydrophilic substituents to form water soluble products that are excretable in URINE. Phase II modifications include GLUTATHIONE conjugation; ACYLATION; and AMINATION. Phase II enzymes include GLUTATHIONE TRANSFERASE and GLUCURONOSYLTRANSFERASE. In a sense these reactions detoxify phase I reaction products.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

The effect of chelating agents on iron mobilization in Chang cell cultures. (1/1100)

The investigation of chelating agents with potential therapeutic value in patients with transfusional iron overload has been facilitated by the use of Chang cell cultures. These cells have been incubated with [59Fe]transferrin for 22 hr, following which most of the intracellular radioiron is found in the cytosol, distributed between a ferritin and a nonferritin form. Iron release from the cells depends on transferrin saturation in the medium, but when transferrin is 100% saturated, which normally does not allow iron release, desferrioxamine, 2,3-dihydroxybenzoic acid, rhodotorulic acid, cholythydroxamic acid, and tropolone all promote the mobilization of ferritin iron and its release from cells. They are effective to an approximately equal degree. The incubation of [59Fe]transferrin with tropolone in vitro at a molar ratio of 1:500 results in the transfer of most of the labeled iron to the chelator, reflecting the exceptionally high binding constant of this compound. How far these phenomena relate to therapeutic potentially remains to be seen.  (+info)

Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. (2/1100)

Juvenile haemochromatosis is a rare inborn error of iron metabolism with clinical manifestations before 30 years of age. Unlike adult haemochromatosis which principally affects men, juvenile haemochromatosis affects the sexes equally; it causes early endocrine failure, dilated cardiomyopathy and joint disease. We report four patients (two of each sex) from three pedigrees affected by juvenile haemochromatosis with a mean onset at 22 years (range 14-30). All had endocrine deficiency with postpubertal gonadal failure secondary to pituitary disease; two suffered near-fatal cardiomyopathy with heart failure. Mean time to diagnosis from the first clinical signs of disease was 9.8 years (range 0.5-20) but general health and parameters of iron storage responded favourably to iron-depletion therapy. A 24-year-old man listed for heart transplantation because of cardiomyopathy [left ventricular (LV) ejection fraction 16%] responded to intravenous iron chelation with desferrioxamine combined with phlebotomy (ejection fraction 31%). A 27-year-old woman with subacute biventricular heart failure refractory to medication required orthotopic cardiac transplantation before the diagnosis was established (LV ejection fraction 25%). Genetic studies showed that these two patients with cardiomyopathy from unrelated families were heterozygous for the HFE 845G-->A (C282Y) mutation and wild-type at the H63D locus: complete sequencing of the intron-exon boundaries and entire coding sequence of the HFE gene failed to identify additional lesions. Two siblings in a pedigree without cardiomyopathy were wild-type at the HFE C282Y locus; although the brother harboured a single copy of the 187C-->G (H63D) allele, segregation analysis showed that in neither sibling was the iron-storage disease linked to MHC Class I markers on chromosome 6p. Juvenile haemochromatosis is thus a genetically heterogenous disorder distinct from the common adult variant.  (+info)

Down regulation by iron of prostaglandin E2 production by human synovial fibroblasts. (3/1100)

OBJECTIVE: To examine the effect of iron on the prostaglandin (PG) E2 production by human synovial fibroblasts in vitro. METHODS: Human synovial fibroblasts were isolated from synovial tissue of rheumatoid arthritis (RA) and osteoarthritis (OA) patients and cultured in medium. Synovial fibroblasts were stimulated by human recombinant interleukin (IL) 1 beta (0.1-10 ng/ml) with or without ferric citrate (Fe-citrate, 0.01-1 mM). The amount of PGE2 in the culture medium was measured by an enzyme linked immunosorbent assay. RESULTS: The production of PGE2 by the synovial fibroblasts was increased by stimulation with IL1 beta at all concentrations tested. Fe-citrate but not sodium citrate (Na-citrate) down regulated the production of PGE2 by the synovial fibroblasts, both with and without stimulation by IL1 beta. Fe-citrate inhibited the spontaneous PGE2 production by the cells in a dose dependent manner, and a maximum inhibition by Fe-citrate was observed at the concentration of 0.1 mM with IL1 beta stimulation. The down regulation by iron was reversed by the co-addition of desferrioxamine (100 micrograms/ml), an iron chelator. CONCLUSION: Iron down regulates the PGE2 production by synovial fibroblasts in vitro.  (+info)

Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. (4/1100)

It has been proposed that cells sense hypoxia by a heme protein, which transmits a signal that activates the heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1), thereby inducing a number of physiologically relevant genes such as erythropoietin (Epo). We have investigated the mechanism by which two heme-binding ligands, carbon monoxide and nitric oxide, affect oxygen sensing and signaling. Two concentrations of CO (10 and 80%) suppressed the activation of HIF-1 and induction of Epo mRNA by hypoxia in a dose-dependent manner. In contrast, CO had no effect on the induction of HIF-1 activity and Epo expression by either cobalt chloride or the iron chelator desferrioxamine. The affinity of CO for the putative sensor was much lower than that of oxygen (Haldane coefficient, approximately 0.5). Parallel experiments were done with 100 microM sodium nitroprusside, a nitric oxide donor. Both NO and CO inhibited HIF-1 DNA binding by abrogating hypoxia-induced accumulation of HIF-1alpha protein. Moreover, both NO and CO specifically targeted the internal oxygen-dependent degradation domain of HIF-1alpha, and also repressed the C-terminal transactivation domain of HIF-1alpha. Thus, NO and CO act proximally, presumably as heme ligands binding to the oxygen sensor, whereas desferrioxamine and perhaps cobalt appear to act at a site downstream.  (+info)

IC202A, a new siderophore with immunosuppressive activity produced by Streptoalloteichus sp. 1454-19. I. Taxonomy, fermentation, isolation and biological activity. (5/1100)

IC202A, a new immunosuppressive compound, was isolated from the culture filtrate of Streptoalloteichus sp. 1454-19. It showed a suppressive effect on mixed lymphocyte culture reaction with an IC50 value of 3.6 microg/ml and mitogen induced lymphocyte blastogenesis in vitro.  (+info)

IC202A, a new siderophore with immunosuppressive activity produced by Streptoalloteichus sp. 1454-19. II. Physico-chemical properties and structure elucidation. (6/1100)

IC202A (1) was isolated from the culture filtrate of Streptoalloteichus sp. 1454-19. The structure of 1 was determined by spectral analysis including a variety of two-dimentional NMR and FAB-MS experiments. IC202A is a ferrioxamine-related compound containing a butylidene N-oxide function.  (+info)

Ferrioxamine-mediated Iron(III) utilization by Salmonella enterica. (7/1100)

Utilization of ferrioxamines as sole sources of iron distinguishes Salmonella enterica serotypes Typhimurium and Enteritidis from a number of related species, including Escherichia coli. Ferrioxamine supplements have therefore been used in preenrichment and selection media to increase the bacterial growth rate while selectivity is maintained. We characterized the determinants involved in utilization of ferrioxamines B, E, and G by S. enterica serotype Typhimurium by performing siderophore cross-feeding bioassays. Transport of all three ferric siderophores across the outer membrane was dependent on the FoxA receptor encoded by the Fur-repressible foxA gene. However, only the transport of ferrioxamine G was dependent on the energy-transducing protein TonB, since growth stimulation of a tonB strain by ferrioxamines B and E was observed, albeit at lower efficiencies than in the parental strain. Transport across the inner membrane was dependent on the periplasmic binding protein-dependent ABC transporter complex comprising FhuBCD, as has been reported for other hydroxamate siderophores of enteric bacteria. The distribution of the foxA gene in the genus Salmonella, as indicated by DNA hybridization studies and correlated with the ability to utilize ferrioxamine E, was restricted to subspecies I, II, and IIIb, and this gene was absent from subspecies IIIa, IV, VI, and VII (formerly subspecies IV) and Salmonella bongori (formerly subspecies V). S. enterica serotype Typhimurium mutants with either a transposon insertion or a defined nonpolar frameshift (+2) mutation in the foxA gene were not able to utilize any of the three ferrioxamines tested. A strain carrying the nonpolar foxA mutation exhibited a significantly reduced ability to colonize rabbit ileal loops compared to the foxA+ parent. In addition, a foxA mutant was markedly attenuated in mice inoculated by either the intragastric or intravenous route. Mice inoculated with the foxA mutant were protected against subsequent challenge by the foxA+ parent strain.  (+info)

The iron regulatory protein can determine the effectiveness of 5-aminolevulinic acid in inducing protoporphyrin IX in human primary skin fibroblasts. (8/1100)

The level of endogenous photosensitiser, protoporphyrin IX (PPIX), can be enhanced in the cells by 5-aminolevulinic acid (ALA). We investigated the effect of critical parameters such as growth state of the cells and availability of intracellular iron in modulating the level of PPIX, in human primary cultured skin fibroblasts (FEK4) maintained either in exponentially growing or growth-arrested phase, following treatment with ALA. The addition of ALA to exponentially growing cells increased the level of PPIX 6-fold relative to control cells; however, in growth-arrested cells the same treatment increased the level of PPIX up to 34-fold. The simultaneous addition of the hydrophilic iron-chelator Desferal with ALA, boosted the level of PPIX up to 47-fold in growing cells and up to 42-fold in growth-arrested cells, suggesting that iron is limiting under the latter conditions. The strict dependence of PPIX enhancement on free available iron levels was examined by the level of activation of iron regulatory protein in band shift assays. This analysis revealed that the basal level of iron regulatory protein in growth-arrested cells was 6-fold higher than in growing cells, reflecting the influence of the free available iron pool in exponentially growing cells. Interestingly, the same ratio was found between the basal level concentration of PPIX in growing and growth-arrested cells. We propose that iron regulatory protein activation could serve as a marker for developing photodynamic therapy protocols because it identifies cells and tissues with a propensity to accumulate PPIX and it is therefore likely to predict the effectiveness of such therapies.  (+info)

TY - JOUR. T1 - Source of iron in neutrophil-mediated killing of endothelial cells. AU - Gannon, D. E.. AU - Varani, J.. AU - Phan, S. H.. AU - Ward, J. H.. AU - Kaplan, J.. AU - Till, G. O.. AU - Simon, R. H.. AU - Ryan, U. S.. AU - Ward, P. A.. PY - 1987/9/10. Y1 - 1987/9/10. N2 - Recently we have shown that human neutrophils activated with phorbol ester are cytotoxic for cultured boving pulmonary artery endothelial cells in an iron-dependent manner. By using the ferric iron chelator deferoxamine mesylate, we have now investigated the source of the iron. Pretreatment of neutrophils with deferoxamine mesylate affected neither their production of O2- nor their cytotoxicity for endothelial cells after addition of phorbol ester. However, similar pretreatment of endothelial cells with deferoxamine mesylate, followed by washing of the cells, resulted in a persistent presence of chelator associated with the endothelial cells and high degrees of protection of endothelial cells from cytotoxicity. The ...
Desferrioxamine Mesylate DBL is a medicine available in a number of countries worldwide. A list of US medications equivalent to Desferrioxamine Mesylate DBL is available on the Drugs.com website.
Clinical reports of deferoxamine-treated thalassemic patients that developed fulminant Y. enterocolitica septicemia are numerous (1, 9, 11, 15). This virulence-enhancing effect of deferoxamine has at least two causes. One is the synthesis by Y. enterocolitica of the outer membrane protein FoxA that acts as a receptor for the exogenous siderophore (6). The other is the modulation and/or abolition of the action of specific and nonspecific immune cells and the inhibition of cytokine production by macrophages, leading to partial immunosuppression of the host (3, 4). Thus, low-pathogenicity Y. enterocolitica strains usually restricted to the digestive tract can use deferoxamine to obtain limiting iron molecules and benefit from the induced immune deficiency to disseminate in their host and cause systemic infections.. Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) is a synthetic iron chelator whose chemical structure (Fig. 4) is completely different from that of deferoxamine (C25H48N6O8 ·CH4O3S). ...
On this page about Desferrioxamine Mesylate (DBL) you will find information relating to side effects, age restrictions, food interactions, whether the medicine is available at a government subsidised price on the pharmaceutical benefits scheme (PBS) as well as other useful information.
Thalassemia major is a genetic disorder affecting hemoglobin synthesis, rendering individuals dependent upon lifelong blood transfusions. Consequently, iron overload occurs and patients have shortened life expectancy with the most common cause of death being heart failure. This trial tests whether the combination of traditional therapy (deferoxamine) with a newer drug (deferiprone) will prove more effective in removing cardiac iron than deferoxamine alone.
This is a prospective, multi-center, double-blind, randomized, placebo-controlled, phase-II clinical trial.. Subjects will be randomized to either deferoxamine mesylate (DFO) at 32 mg/kg/day (up to a maximum daily dose of 6000 mg/day), or saline placebo, given by IV infusion for 3 consecutive days.. Treatment will be initiated within 24 hours after ICH symptom onset. Randomization will control baseline imbalances associated with baseline ICH score, ICH onset-to-treatment time (OTT), ICH volume, baseline NIHSS score, and warfarin use.. All subjects will be followed for 6 months and will receive standard of care therapy while participating in the study.. Throughout the study, we will continue to assess the safety of DFO. At the conclusion of the study, the proportion of DFO-treated subjects with a good clinical outcome at 3 months (defined as modified Rankin Scale (mRS) score of 0-2) will be compared to the placebo proportion in a futility analysis to determine if it is futile to move DFO forward ...
Neural Regen Res. 2017 Jun;12(6):959-968. Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats. Hao J1, Li B1, Duan HQ1, Zhao CX1, Zhang Y1, Sun C1, Pan B1, Liu C2, Kong XH2, Yao X1,3, Feng SQ1,3. Author information Abstract Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism for this action remains unknown. Here, we determined whether deferoxamine was
The objective of this research study is to determine the safety and feasibility of chelation therapy with deferoxamine for patients with iron overload who are receiving a stem cell transplant. Patients who have iron overload prior to stem cell transplantation may have more toxicity from the transplantation procedure, and thus may benefit from an attempt at iron chelation pre- and peri-transplantation. In this study we are examining the use of deferoxamine starting 2 weeks to 3 months prior to transplantation and continuing through the preparative regimen ...
Acute myocardial infarction (AMI) is followed by free radicals generation, which is central in cardiac remodeling. N-acetylcysteine (NAC) is an antioxidant that may have pro-oxidant activity in presence of iron ions. Thus, the association with an iron chelator might improve NAC antioxidant potential. Our aim was to test the association of NAC and an iron chelator (deferoxamine - DFX) on cardiac remodeling in a rodent model of AMI. To this end, Male Wistar rats (60 days old) were subjected to a sham surgery or subjected to myocardial infarcted by the occlusion of left ventricular descending artery. Twelve hours after, AMI was confirmed by cTnI evaluation and the animals were randomized in the following treatments: vehicle, NAC (25 mg/kg for 28 days), DFX (40 mg/kg for 7 days), or NAC plus DFX (NAC 25 mg/kg for 28 days plus DFX 40 mg/kg for 7 days). All animals were followed for 28 days. AMI induced an increase in total plasma iron levels at 7 days after the procedure and all treatments were able ...
Glutathione (GSH), an abundant tripeptidyl molecule, plays pivotal roles in protecting cells against oxidative stress-induced cellular damage and in detoxifying xenobiotics and drug metabolism. GSH is now entering a new era of therapeutic applications. Decreased GSH levels are associated with the common features of aging as well as of a wide range of pathological conditions, including neurodegenerative disorders. Notably, GSH depletion and/or alterations in its metabolism appear to be crucial in the onset of Parkinsons disease. Despite the fact that GSH is required for cell survival, the molecular mechanism that links GSH depletion to cell death remains poorly understood. Recently, considerable attention has been focused on a newly defined type of cell death: irondependent cell death, also referred to as ferroptosis. The iron chelator deferoxamine nearly abolishes ferroptosis induced by inhibiting GSH synthesis or cystine uptake by the xCT transporter. Deferoxamine preferentially abrogates ...
Het huidige werk beschrijft de ontwikkeling van een op nanopapier gebaseerd analytisch apparaat (NAD), door het inbedden van curcumine in transparant bacterieel cellulose (BC) nanopapier, als een colorimetrische testkit voor het monitoren van ijzer en deferoxamine (DFO) als ijzer- chelaatvormer in biologische vloeistoffen zoals serumbloed, urine en speeksel. De ijzerdetectiestrategie met behulp van de ontwikkelde testkit is gebaseerd op de afname van de absorptie / kleurintensiteit van curcumine ingebed in BC-nanopapier (CEBC) in aanwezigheid van Fe (III), als gevolg van de vorming van Fe (III) -curcumine complex.. Aan de andere kant, het vrijkomen van Fe (III) uit Fe (III) -CEBC na toevoeging van DFO als een ijzerchelerend medicijn, vanwege de hoge affiniteit van dit medicijn voor Fe (III) in competitie met curcumine, wat leidt tot herstel van de verminderde absorptie / kleurintensiteit van Fe (III) -CEBC, wordt gebruikt voor selectieve colorimetrische monitoring van dit medicijn. De ...
Deferoxamine, used to treat iron overload, can be used to prevent leukemia cells from overtaking stem cell sites in the bone marrow.
The Intracerebral Hemorrhage Deferoxamine (iDEF) trial will study the effects of deferoxamine on brain or intracranial hemorrhage (ICH). This trial also will help researchers learn more about the safety of the drug. ICH occurs when a blood vessel in the brain bursts open. This causes blood to leak into the brain and may lead to a hemorrhagic stroke. A hemorrhagic stroke occurs when blood flow to a part of the brain stops. The blood in the brain also contains iron, which damages the brain. The focus of this multi-center, double-blind, placebo-controlled study is to evaluate deferoxamine.... ...
Hypoxia is a key factor in tumor development, contributing to angiogenesis and radiotherapy resistance. Hypoxia-inducible factor-1 (HIF-1) is a major transcription factor regulating the response of cancer cells to hypoxia. However, tumors also contain areas of more severe oxygen depletion, or anoxia. Mechanisms for survival under anoxia are HIF-1alpha independent in Caenorhabditis elegans and, thus, differ from the hypoxic response. Here we report a differential response of cancer cells to hypoxia and anoxia by demonstrating the induction of activating transcription factor-4 (ATF-4) and growth arrest DNA damage 153 (GADD153) protein specifically in anoxia and the lack of induction in hypoxia. By applying RNAi, ATF-4 induction in anoxia was shown to be independent of HIF-1alpha, and desferrioxamine mesylate (DFO) and cobalt chloride induced HIF-1alpha but not ATF-4 or GADD153. Furthermore, the inductive response of ATF-4 and GADD153 was not related to alterations in or arrest of mitochondrial respiration
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The National Institute of Standards and Technology (NIST) uses its best efforts to deliver a high quality copy of the Database and to verify that the data contained therein have been selected on the basis of sound scientific judgment. However, NIST makes no warranties to that effect, and NIST shall not be liable for any damage that may result from errors or omissions in the Database ...
Easy-to-read patient leaflet for Desferal. Includes indications, proper use, special instructions, precautions, and possible side effects.
Find the Blink Price & Information for Desferal - as low as $1,072.80 - pick up at your pharmacy (Rite Aid, Walmart & more). Price transparency and up to 80% savings.
The usual directionsAs of the CO2 download the complete guide to eco were social Pharmacological novelty in June and July, and low ecosystems in April and from September to October, with the highest alleles in July 2015. The realistic services from 2013 to 2015 were higher than the last output, then clonal to sustained biomolecules in surface. index had below the temporal source, independently because of nuclear desferrioxamine in caries.
Acute administration of iron to rats has been previously shown to induce liver ferritin synthesis by increasing the translation of inactive cytoplasmic ferritin mRNAs for both heavy (H) and light (L) subunits by mobilizing them onto polyribosomes. In this report rat hepatoma cells in culture are used to explore the relationship of this response to intracellular iron levels. After adding iron as ferric ammonium citrate to the medium, latent ferritin H- and L-mRNAs were extensively transferred to polyribosomes, accompanied by increased uptake of [35S]methionine into ferritin protein. Because total cellular levels of L- and H-mRNA were not significantly changed by exposure to iron, the increased ferritin mRNAs on polyribosomes most probably come from an inactive cytoplasmic pool, consistent with the inability of actinomycin-D and of cordycepin to inhibit iron-induced ferritin synthesis. When deferoxamine mesylate, an intracellular iron chelator, was added after the addition of iron to the medium, ferritin
Recently, it was reported that nitric oxide (NO) directly controls intracellular iron metabolism by activating iron regulatory protein (IRP), a cytoplasmic protein that regulates ferritin translation. To determine whether intracellular iron levels themselves affect NO synthase (NOS), we studied the effect of iron on cytokine-inducible NOS activity and mRNA expression in the murine macrophage cell line J774A.1. We show here that NOS activity is decreased by about 50% in homogenates obtained from cells treated with interferon gamma plus lipopolysaccharide (IFN-gamma/LPS) in the presence of 50 microM ferric iron [Fe(3+)] as compared with extracts from cells treated with IFN-gamma/LPS alone. Conversely, addition of the iron chelator desferrioxamine (100 microM) at the time of stimulation with IFN-gamma/LPS increases NOS activity up to 2.5-fold in J774 cells. These effects of changing the cellular iron state cannot be attributed to a general alteration of the IFN-gamma/LPS signal, since ...
A radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody J591 against prostate-specific membrane antigen (PSMA) conjugated to chelator desferrioxamine B (DFO-B) and labeled with the radioisotope zirconium Zr 89 with potential imaging property used in positron emission tomography (PET) imaging. Upon administration of zirconium Zr 89 desferrioxamine B monoclonal antibody huJ591, the antibody moiety binds to the extracellular domain of PSMA, and the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of PSMA-expressing tumor cells. PSMA, or folate hydrolase is a cell surface peptidase highly expressed by malignant prostate epithelial cells and vascular endothelial cells of numerous solid tumor malignancies. In addition, upon PET imaging this agent provides high tumor:background tissue ratios. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus ...
Two humic acids extracted from a volcanic soil (HA1) and a leonardite (HA2) were used to form insoluble complexes with iron metals. To simulate the rhizospheric processes that displace iron from complexes of humic molecules and solubilize the soil humeome, the insoluble iron-humates were treated with a solution of siderophore deferoxamine mesylate (DFOM) and a mixture of citric, oxalic, tartaric and ketoglutaric acids, at different concentrations and contact times. Results showed that the removal of iron from humic complexes varied depending on the concentration of the extractants and extraction times. At large concentration, the mixture of organic acids was generally a better extractant than the siderophore, probably because of their lower solution pH. However, at smaller concentrations, the extracting capacity of the DFOM solution and the mixture of organic acids was generally similar. Differences in iron extractability between the two iron-humates were attributed to both the humic molecular
This study investigated if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a
METHODS AND RESULTS Injury was induced by inflation of a balloon catheter 50 +/- 6% above baseline arterial diameter; dogs were followed for 2 hours before death. Epicardial coronary diameters at arteriography and extent of thrombus deposition at serial histological sections were analyzed in controls (n = 20) and in dogs pretreated with superoxide dismutase (SOD, a superoxide radical scavenger, n = 10); other dogs were pretreated with the hydrogen peroxide scavenger catalase (n = 8), the iron chelator deferoxamine (n = 6), or the hydroxyl radical scavenger 1,3-dimethyl-2-thiourea (n = 9). Angioplasty-induced injury was similar among groups. After angioplasty, control dogs exhibited localized and persistent vessel constriction, which was maximal at the initial 5 minutes (28.9 +/- 6.3% diameter decrease versus baseline). Corresponding arterial diameters of SOD-treated dogs were 24-69% larger (95% confidence interval, p less than 0.001) than controls at 5 minutes and, on average, 32% larger than ...
Deferoxamine, a drug already FDA-approved for the treatment of disorders related to excess iron in the blood, may help doctors heal stubborn leg and foot wounds in people with diabetes. Scientists at the Stanford University School of Medicine and the Albert Einstein College of Medicine found that with deferoxamine, small cuts in diabetic mice healed 10 days faster than they did in untreated mice: 13 days as opposed to 23 days. If deferoxamine works similarly on humans, it could significantly speed the healing of diabetic wounds.. Diabetic wounds heal slowly because the body doesnt do a good job of creating new blood vessels to reconnect the damaged tissue to the oxygen-bearing bloodstream. Previously, scientists didnt know why these new connections didnt take place. Now, based on the Stanford/Einstein study, they believe that the high-glucose environment of diabetic tissue prevents the production of a necessary vessel-building factor known as VEGF.. VEGF, or vascular endothelial growth ...
Enlarged or giant mitochondria have often been documented in aged tissues although their role and underlying mechanism remain unclear. We report here how highly elongated giant mitochondria are formed in and related to the senescent arrest. The mitochondrial morphology was progressively changed to a highly elongated form during deferoxamine (DFO)-induced senescent arrest of Chang cells, accompanied by increase of intracellular ROS level and decrease of mtDNA content. Interestingly, under exposure to subcytotoxic doses of H2O2 (200 µM), about 65% of Chang cells harbored elongated mitochondria with senescent phenotypes whereas ethidium bromide (EtBr) (50 ng/ml) only reformed the cristae structure. Elongated giant mitochondria were also observed in TGF β1- or H2O2-induced senescent Mv1Lu cells and in old human diploid fibroblasts (HDFs). In all senescent progresses employed in this study Fis1 protein, a mitochondrial fission modulator, was commonly downexpressed. Overexpression of YFP-Fis1 ...
This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood tran
Others ferritin, transferrin..it is always in ferric form. Ohh. Interesting!. Antidote for choice for acute iron overdose? Desferoxamine?. Yup. Desferrioxamine is given IV.. It is for acute iron overload. Which antidote is preferred for chronic iron overdose then?. Oral drug.. Deferiprone ...
In the insulin-secreting beta cell line RINm5F, sodium fluoride stimulated exocytosis in a concentration (5-15 mM)- and temperature-dependent manner. Depletion of aluminum with the chelator deferoxamine or addition of aluminum to the buffer failed to affect the NaF-stimulated insulin release. This suggests that stimulation of heterotrimeric G proteins or inhibition of phosphatases or other enzymes by fluoroaluminate, an analog of the phosphate moiety, is not involved in the insulinotropic action of NaF. Removal of extracellular Ca2+ suppressed the NaF-stimulated insulin release. However, nitrendipine, a blocker of L-type voltage-dependent Ca2+ channels, did not inhibit the NaF-stimulated insulin release and NaF did not cause any changes in the cytosolic free calcium concentration ([Ca2+]i). Decreasing [Ca2+]i with thapsigargin or increasing [Ca2+]i with ionomycin or a depolarizing concentration of KCl resulted in suppression or enhancement of NaF-stimulated insulin release, respectively. ...
The foxA gene encoding the Salmonellaferrioxamine receptor was first identified as a cloned subgenic fragment having a deduced amino acid sequence that was 45% identical to the amino acid sequence of the specific outer membrane ferrioxamine receptor of Y. enterocolitica (44). Phenotypic analysis of foxA mutants carrying either a pMAP insertion (potentially polar) mutation or a defined nonpolar frameshift mutation demonstrated that the FoxA protein is required for utilization of all three ferrioxamine molecules tested. Moreover, using the subgenicfoxA fragment as a probe, we showed that the foxAgene is not ubiquitous among Salmonella serotypes but is limited to subspecies I, II, and IIIb. The presence of foxAcorrelated with growth stimulation by ferrioxamine E in bioassays; strains that were negative as determined by hybridization were also negative in bioassays performed with ferrioxamine E. Although this observation may suggest that inclusion of ferrioxamines as medium supplements would not be ...
https://www.facebook.com/pages/CCSVI-in ... 1035992211 Minocycline and desferoxamine are two pharmaceutical options that could prove helpful for people whose CCSVI does not fully resolve after venoplasty. And there are undoubtedly others. Great post by Marie.
Our research is aimed at better understanding the fundamental chemistry associated with the treatment of iron-overload. Iron-overload is prevalent in people who cannot produce red blood cells and require repeated blood transfusions. The treatment involves co-administration of desferrioxamine B and vitamin C, which can generate free radicals through Fenton type reactions where the iron cycles between the +2 and +3 oxidation states. Our research is currently focused on translating our previous results from in vitro conditions to E. coli and other more biologically applicable model systems.
modelling Up the websites of the Desferrioxamine B Jigsaw Defines the Biosynthetic Sequence Catalyzed by DesD. ACS Chemical Biology, 11(5), 1452-1462. perpetual subcontractor of Humanity, way and unit by Shewanella plans and law of supplies with schools), molybdenum(VI) or chromium(V).
One pack of Injection Desferal [10 injections in a pack] costs Rupees 2800 / 26 USD, On an average #thalassemia patient needs 6 packs in a month, please help us in the noble cause.. You can donate even for half pack! Please contribute.. ...
Anemia is not infrequently found in diabetic patients. In addition, Rosen and Tullis (JAMA 195: 261, 1966) have reported abnormally low deferoxamine chelation values in nonanemic diabetic patients suggesting that there is a defect in iron metabolism associated with this disease. The erythrokinetics in 42 non-iron-deficient diabetic patients were therefore studied. These 42 patients included about 17 without anemia or clinical evidence of renal disease, 11 with anemia but without renal disease, and 14 with both anemia and renal disease. Although there is some overlapping of values for individual patients in the 3 groups, each group has a combination of ...
worth. Rawhides are notorious for causing an obstruction in the gut. my 270-pound dogs ate a whole bag of maximum strength hip and joint glucosamine 600 mg MSM to 10 mg equal to 10mg total amount … read more. Help! Hes had them before. Possible causes for dog glucosamine overdose. My dog got into her science diet dog food bag and ate too much now she has a tummy ache,gas, and is bloated. She probably threw up because she ate too much to digest properly. People at the dog park asked, what are you feeding Chaco and Denali when I started giving them these treats that I found at Whole Foods. The dog was treated with deferoxamine and supportive care. If given in high amounts, the dog may have a negative reaction to glucosamine. It wont hurt her to miss a meal or two as long as she is drinking water. For example, glucosamine is today found in everything ranging from senior dog food to dog treats and supplements. Should we take her to emergency vet? My 30 lbs dog ate almost an entire bag of ...
You may also wish to search for items by Vennerstrom. Only one matching reference was found. Ihnat, Peter M.; Vennerstrom, Jonathan L.; Robinson, Dennis H., Synthesis and solution properties of deferoxamine amides, J. Pharm. Sci., 2000, 89, 12, 1525-1536, https://doi.org/10.1002/1520-6017(200012)89:12,1525::AID-JPS3,3.0.CO;2-T . [all data] ...
A place for Thalassemia patients, family, friends, and medical professionals, to gather for information on Thalassemia and related issues.
A properly sized ProMate 6 Iron Curtain (IC) 2.0 system requires no chemicals and regenerates every three days; many of our competitors systems require daily regeneration. This could save you as much as 2,000 gallons per month! ...
I bought a Roland TD-4 KX2 kit for church several years ago, and while it has been a godsend for my hearing issues, the only thing left from the original...
Iron plays a critical role in host-parasite interactions, and iron chelators have been demonstrated to serve as effective adjunct therapeutic agents against malaria. The effects of the parenteral iron chelator deferoxamine (DFO) on the growth of rat-derived Pneumocystis carinii were studied in a human fibroblast cell culture model and in two in vivo models of experimental infection. In addition, the effects of the investigational oral iron chelator CP20 and its 3-hydroxypyridin-4-one analogs CP51, CP94, and CP96 on the growth of P. carinii in vitro were assessed. DFO suppressed the growth of P. carinii in vitro in a dose-dependent manner, and daily injections of DFO markedly reduced the intensity of P. carinii infection in both mice and rats. Cell cultures treated with iron chelators that are administered orally to humans also showed substantial P. carinii growth inhibition. Reduction of P. carinii numbers after iron chelator therapy correlated with alterations in P. carinii morphology, as ...
BACKGROUND: Relatively little is known about endocrine function, bone mineral health, and growth during oral iron chelation therapy in β-thalassemia major patients (TM) on treatment with deferasirox. AIMS OF THE STUDY: To study the frequency of endocrine complications, IGF-1 levels and final adult standing height (FA-Ht) in patients with BTM in two groups of adult patients. PATIENTS AND METHODS: The first group (Group A; 15 patients, 6 females and 9 males) received oral iron chelation therapy (OIC) with deferasirox for 6 years before puberty; the second group (Group B;40 patients) attained the FA-Ht before the use of OIC (iron chelation therapy with deferoxamine (DFO) given subcutaneously, since the age of 2 years ...
1. The sera of patients with idiopathic haemochromatosis and iron-overload have been found to contain low-molecular-weight iron complexes detectable in the bleomycin assay.. 2. These complexes stimulate both the peroxidation of membrane lipids and the formation of the highly reactive and damaging hydroxyl radical.. 3. The iron chelator desferrioxamine interferes with these reactions.. 4. We suggest that oxygen radical reactions stimulated by iron salts are important in the pathology of idiopathic haemochromatosis.. ...
Italys Chiesi Global Rare Diseases has gained approval from the US Food and Drug Administration (FDA) for the expanded use of its sickle cell disease (SCD) treatment Ferriprox. Ferriprox (deferiprone) is now approved in the US for the treatment of transfusional iron overload due to SCD or other anaemias in adult and paediatric patients aged three years or older.. The new approval expands the use of Ferriprox beyond its other indication, where it is approved to treat patients with transfusional iron overload due to thalassemia syndromes.. In the US, SCD affects approximately 100,000 people and is associated with a lower life expectancy of over 20 years compared with the general population.. Ferriprox, a synthetic and orally active iron-chelating agent, is designed to penetrate cell membranes and remove toxic iron from organ tissues and extracellular fluids.. In a study comparing the efficacy of Ferriprox to deferoxamine in patients with SCD and other transfusion-dependent anaemias, Chiesis drug ...
Hydroxytyrosol (HT) is a natural phenolic antioxidant which has neuroprotective effects in models of Parkinsons disease (PD). Due to issues such as rapid metabolism, HT is unlikely to reach the brain at therapeutic concentrations required for a clinical effect. We have previously developed micellar nanocarriers from Pluronic F68® (P68) and dequalinium (DQA) which have suitable characteristics for brain delivery of antioxidants and iron chelators. The aim of this study was to utilise the P68 + DQA nanocarriers for HT alone, or in combination with the iron chelator deferoxamine (DFO), and assess their physical characteristics and ability to pass the blood-brain barrier and protect against rotenone in a cellular hCMEC/D3-SH-SY5Y co-culture system. Both HT and HT + DFO formulations were less than 170 nm in size and demonstrated high encapsulation efficiencies (up to 97%). P68 + DQA nanoformulation enhanced the mean blood-brain barrier (BBB) passage of HT by 50% (p 0.0001, n = 6). This resulted in ...
Thank you for your interest in spreading the word about Haematologica.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
This study investigated the safety, pharmacokinetics and efficacy of deferoxamine and deferitrin [GT56-252; Genzyme Corporation] in patients with transfusional
The exact meaning of the medical terminology,Deferoxamine - An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and causing cancer cell death. It is used in conjunction with other anticancer agents in pediatric neuroblastoma therapy, is clearly explained in Medindia s glossary of medical terms
Participants were randomized into two groups: 290 received deferoxamine infusions five days a week; 296 drank deferasirox dissolved in water each day before breakfast. Drug dosages were determined by each patients liver iron concentration (LIC) level; those with higher levels received increased doses. Since LIC values above 7 mg Fe/g dw are associated with increased morbidity and mortality, the primary goal of the trial was to reduce LIC levels in those with high values and maintain LIC levels in those with low values. At the beginning of the study, more than two-thirds of the participants had at-risk LIC levels ...
60 to 70 million Americans suffer form heart attacks. Over 550,000 will die this year from heart attacks and the numbers are increasing. The cost of treating heart attacks in the US is estimated at 50-60 billion dollars a year. Conventional treatments for heart disease have been, by pass surgery and angioplasty. These life saving treatments have been recognized by the medical industry the standard necessary procedures.. Chelation therapy has been known about for over 60 years, The medical industry prefers not to recognize a procedure that has the ability to prevent much unnecessary surgery and suffering. Heart disease is a very big and profitable business. Its very easy to pay the overhead on a large medical facility when the operating rooms are constantly filled with heart patients.. Chelation therapy as practiced in Florida has been proven to increase blood flow and to remove plaque build up in the arteries. Chelation therapy is a safe and effective method of eliminating scale or plaque, that ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
1. Altstiel L, Sperber K. Cytokines in Alzheimers disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481 495. 2. Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimers disease cortices. FEBS Lett 1991;285:111 114. 3. Behl C, Davis J, Cole GM, et al. Vitamin E protects nerve cells from amyloid B protein toxicity. Biochem Biophys Res Commun 1992;186:944 950. 4. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797 811. 5. Caporaso GL, Gancy SE, Buxbaum JD, et al. Chloroquine inhibits intracellular degradation but not secretion of Alzheimer B/A4 amyloid precursor protein. Proc Natl Acad Sci USA 1992;89:2252 2256. 6. Chang TMS, Barre P. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis. Lancet 1983;1051 1053. 7. ...
The primary health problem affecting the arteries is arteriosclerosis. An artery is comprised of three basic layers: an inner layer known as the intima, a middle layer called the media, and an outer layer known as the adventitia. In some cases of arteriosclerosis yellowish plaques, called atheromas, develop within the intima and medial layers of the larger arteries. These plaques contain cholesterol, fatty materials, proteins and minerals. Another form of arteriosclerosis occurs when deposits of calcium develop within the media of the larger arteries. Chelation therapy works by attacking the calcium deposits in the arteries. Calcium exists in the body in many forms. Calcium in the bones and teeth is firmly bound to protein and other molecules and is not easily removed by chelation. Calcium in the blood may be bound in part by protein or in a readily available ionic form. This ionic level of calcium is rigidly controlled by the parathyroid gland. Chelation works by removing calcium from the blood ...
Several researchers have developed a modified way to do intravenous chelation therapy. This has come about from a better understanding of how chelation works. The standard method, which has been used since the 1940s on many thousands of patients, is still a good method. The new method uses a calcium EDTA that can be infused faster and works well to remove heavy toxic metals, including mercury, lead, arsenic, nickel, and cadmium. All of these are fairly commonly found in todays toxic environment. So far, studies seem to indicate that it is just as good to clean out arterial plaque as the older method. It does not, however, have the long track record as the older method.. If only the calcium EDTA is used, it is safe to infuse in as little as one minute for most people. However, many feel a major benefit of the chelation process is to include some vitamins and minerals with it as is done in the older method. Thus we include these in a 100 ml bag (rather than 250 or 500) and infuse it in ...
Chelation therapy involves the administration of chelating agents to treat toxic metal poisoning. These chelating agents or chelants are used to remove heavy metals from the body in cases of overdose, poisoning or accumulation. The chelants are ligands that bind to metals present in the blood and tissues.
Chelation therapy is used to counter the massive build-up of metal in the human body. These heavy metals include arsenic, lead, and mercury. The danger is that it could potentially cause poisoning, if
I had mercury poisoning for 3 years before having them drilled out. Then I did chelation therapy for a month and came out of it with the help of the chelated minerals. I know they worked. This was way way back in 1991. The mercury prevented my system from fully digesting proteins and then that caused many complications: stomach problems, muscle fatigue, intolerance to other foods, impotence and general ill feelings. A led to b which led to c which led to c-1, c-2 , c3 etc ...
15d-PGJ2 ( 54 ) , A23187 ( 95 ) , acetyl-boswellic_acid ( 84 ) , AG1478 ( 39 ) , AGEs ( 15 ) , AH6809 ( 45 ) , Akt-I-1,2 ( 8 , 52 ) , angiotensin_2 ( 63 ) , anti-CD28 ( 91 ) , anti-CD3 ( 91 ) , anti-CD3/CD28 ( 33 , 88 ) , anti-LT(beta)R ( 98 ) , antitrypsin ( 59 ) , bacterial infection ( 24 , 86 ) , Bay_11-7082 ( 14 , 32 , 95 ) , BI-D1870 ( 15 ) , bisindolylmaleimide ( 91 ) , bortezomib ( 72 ) , botulinum_C3_toxin ( 63 ) , Ca(2+) ( 12 ) , calyculin_A ( 32 , 95 ) , CCL5 ( 52 ) , ciclosporin ( 33 ) , cisplatin ( 23 ) , CmpdA ( 23 ) , compound_1 ( 26 ) , deferoxamine ( 60 ) , delphinidin ( 55 ) , dimethylfumarate ( 22 ) , double-stranded_RNA ( 67 ) , DPI ( 25 , 57 ) , EGF ( 50 ) , epoxomicin ( 72 ) , ethanol ( 64 ) , farnesol ( 56 ) , fluid_shear_stress ( 45 ) , genistein ( 68 ) , gomisin_A ( 35 ) , gomisin_N ( 35 ) , GSK-3_inhibitor_X ( 42 ) , H-89 ( 45 ) , heat_shock ( 34 ) , IFN-gamma ( 42 ) , IKK-beta_inhibitor_IV ( 32 ) , IL-1a ( 62 , 73 , 74 ) , IL-1b ( 10 , 19 , 26 , 53 , 79 , 85 , 95 ) , ...
Few side effects occur when chelating agents are administered for approved indications using the recommended dosage and route of administration.
Hello doctor. Im a long-term cardiac patient who has been invited (by my cardiologist)to participate in clinical study of chelation therapy. Would you please give me an overview of this therapy? Spe...
Angioprim is an effective method in cleaning blocked arteries and veins. Plaque prevention promotes a healthy cardiovascular system and can lead to a healthier, longer life. Its powerful chelating action helps remove plaque from the arteries quicker.
See chelation therapy reviews from people who are using Detoxamin. Detoxamin will revolutionize medicine Dr Sherry Rogers. Read chelation therapy reviews.
Find your LIFT-ALL SLINGS WEB POLYESTER at Acklands-Grainger. We have been Canadas premiere industrial supplier for over 125 years with superior service and quality.
Eventbrite - The Accelerator Centre presents Accelerate DFx - Wednesday, 25 October 2017 at Kitchener City Hall - Council Chambers, Kitchener, ON. Find event and ticket information.
Get a smooth, non-impact workout that will help increase flexibility, quickness, range of motion, finger and grip strength. Not only will this improve your game, but it will help prevent the repetitive stress injuries that would mean Game Over.
4,5-dihydro-2-(2-hydroxy-4-(12-amino-5,9-diazadodecyloxy)phenyl)-4-methyl-4-thiazolecarboxylic acid: putative vector for iron chelators; structure in first source
I loved the Cappella JC sticks ..... still have a few pair. What Id really like to get hold of are a couple of pairs of their brushes. I checked them out at NAMM the year they closed ....... and that was after it was possible to buy things at the show ...
IC: One of the issues with 3D stacking, especially as you go beyond two stacks which is where Intels future lies, is getting enough combined dies to yield appropriately. Can you talk about the redundancy thats built into Intels stacking technologies, and how this helps?. RN: So we do have redundancy built in. We do a lot of really heavy use of DFX, which stands for Design for X, which could be designing for test, or design for yield, and we scan at each stage. There is also singulated die test technology that we can do before stacking the dies to ensure that were putting two guaranteed known good die together before they become a package. So between the kind of design for yield/design for test and advanced testing capabilities, this is how we will move forward in terms of guaranteeing known good die. You are right, its an important factor to discuss, especially not only because its the yield of the die but also the yield of the process of combining those die.. DS: Do you see that ...
Popular chelators include deferoxamine and deferiprone. The oral chelator deferasirox was approved for use in 2005 in some ... "Deferoxamine". livertox.nih.gov. Retrieved 2015-05-26. Sabloff, Mitchell; Chandy, Mammen; Wang, Zhiwei; Logan, Brent R.; ... The three iron chelators; subcutaneous deferoxamine, oral deferiprone and oral deferasirox can be used as monotherapy or in ... The excess iron can be removed by iron chelators (deferoxamine, deferiprone and deferasirox). Luspatercept (ACE-536) is a ...
Deferoxamine is a drug that is used in cases of serious iron poisoning. It is a chelating agent and binds to free iron in the ... Deferoxamine can be administered intramuscularly as a single dose where it then binds to free iron in the blood and is excreted ... The deferoxamine challenge test is a diagnostic test for confirming iron poisoning, however it is no longer recommended for ... Dosing of deferoxamine should be determined through consultation with a toxicologist but is typically continuously infused at ...
May 2018). "Deferoxamine can prevent pressure ulcers and accelerate healing in aged mice". Wound Repair and Regeneration. 26 (3 ... January 2015). "Transdermal deferoxamine prevents pressure-induced diabetic ulcers". Proceedings of the National Academy of ... August 2019). "Optimization of transdermal deferoxamine leads to enhanced efficacy in healing skin wounds". Journal of ...
May 2018). "Deferoxamine can prevent pressure ulcers and accelerate healing in aged mice". Wound Repair and Regeneration. 26 (3 ... January 2015). "Transdermal deferoxamine prevents pressure-induced diabetic ulcers". Proceedings of the National Academy of ... March 2017). "Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and ... August 2019). "Optimization of transdermal deferoxamine leads to enhanced efficacy in healing skin wounds". Journal of ...
The medical management of iron toxicity is complicated, and can include use of a specific chelating agent called deferoxamine ... "Benefits of parenteral deferoxamine for acute iron poisoning". J Toxicol Clin Toxicol. 34 (5): 485-89. doi:10.3109/ ... "Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine". J Toxicol Clin Toxicol. 33 (1): 61 ...
Kim, Choon-Mee; Park, Yong-Jin; Shin, Sung-Heui (2007-11-15). "A widespread deferoxamine-mediated iron-uptake system in Vibrio ...
Deferoxamine is only effective via daily injections which makes its long-term use more difficult. It has the benefit of being ... Iron chelation may be done with deferoxamine, deferasirox or deferiprone. Occasionally, a bone marrow transplant may be an ... The iron overload related to thalassemia may be treated by chelation therapy with the medications deferoxamine, deferiprone, or ...
There are three common iron chelators, including deferoxamine, deferiprone and deferasirox. Deferoxamine is injected into the ... Deferoxamine is seldom used alone nowadays, but rather in combination with oral deferiprone to increase the effectiveness in ... It shares similar benefits of convenience with deferiprone when compared to deferoxamine, but however is of the highest cost. ... Iron chelation therapy is used to treat iron overload and common iron chelators used are deferoxamine, deferiprone and ...
"Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine". Journal of Toxicology. Clinical ...
... either deferoxamine, deferasirox, or deferiprone to eliminate the excess iron that accumulates. Removal of the spleen and ...
Deferoxamine, a chelating agent, is used to treat iron overload from transfusions. Therapeutic phlebotomy can be used to manage ...
Deferoxamine, deferiprone and deferasirox are the three most widely used iron-chelating agents. The drug deferoxamine, also ... The toxic effect of deferoxamine on linear growth could also be due to excess deferoxamine accumulating in tissues and ... Deferoxamine has an affinity constant (Ka) of 1031 for Fe3+, 1014 for Cu2+ and 1010 for Zn2+, and so may coordinate to zinc and ... Deferoxamine could lead to toxic side effects if doses greater than 50 mg/kg body weight are administered. These side effects ...
He tells the team to treat her with deferoxamine and says 'She'll be fine by lunch.' Foreman scans her, and remarks "There's ... To which House dismisses by saying "Someone you like." Chase is administrating the deferoxamine, but her alveoli sacks rip and ...
In iron chelation therapy, deferoxamine, has been used to treat excess iron stores, i.e. haemochromatosis. Xue, Hanbin; Sigg, ...
The drug deferoxamine binds with iron in the bloodstream and enhances its elimination in urine and faeces. Typical treatment ...
Treatment is by phlebotomy, erythrocytapheresis or chelation therapy with iron chelating agents such as deferoxamine, ...
When the cause is an iron overload then the iron is removed using a chelation agent such as deferoxamine. Regardless of the ...
deferoxamine, a naturally occurring siderophore produced by the actinobacter Streptomyces pilosus and was used initially as a ... Synthetic siderophores such as deferiprone and deferasirox have been developed, using the known structure of deferoxamine as a ...
There is insufficient evidence that iron chelating agents such as deferoxamine and deferiprone improve outcomes of those with ...
Sample gallery Ferrichrome Deferoxamine Rhodotorulic acid Fe(III) complex of triacetylfusarinine In the area of coordination ...
Patients undergoing iron chelation therapy with deferoxamine are also at risk of infection, because this treatment also ...
Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be ...
Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major ...
April 2007). "A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and ...
Although this method has only a limited efficacy, unlike small-molecular chelators (deferasirox, deferiprone, or deferoxamine ...
... and deferoxamine therapy.[medical citation needed] Despite this, however, there have been cases of mucormycosis reported with ...
... a chemical that makes fingerprints glow when lit by laser or blue-green light Deferoxamine, a bacterial chelating agent used to ...
In case of suspected sudden intake of a large amount of aluminium, the only treatment is deferoxamine mesylate which may be ...
Naloxone Penicillamine Prussian blue Sodium nitrite Sodium thiosulfate Deferoxamineα Dimercaprolα Fomepizoleα Sodium calcium ... Protamine sulfate Tranexamic acid Warfarin Desmopressinα Heparin sodiumα Protamine sulfateα Warfarinα Deferoxamineα ...
... activated Acetylcysteine Atropine Calcium gluconate Naloxone Deferoxamineα Dimercaprolα Fomepizoleα Sodium calcium edetateα ... agents Enoxaparin Phytomenadione Desmopressinα Heparin sodiumα Protamine sulfateα Warfarinα Deferoxamineα Hydroxycarbamideα ...
Deferoxamine is a siderophore from the bacteria Streptomyces pilosus. Deferoxamine was approved for medical use in the United ... Chronic use of deferoxamine may cause ocular symptoms, growth retardation, local reactions and allergy. Deferoxamine is ... Deferoxamine (DFOA), also known as desferrioxamine and sold under the brand name Desferal, is a medication that binds iron and ... Deferoxamine is used to treat acute iron poisoning, especially in small children. This agent is also frequently used to treat ...
The National Institute of Standards and Technology (NIST) uses its best efforts to deliver a high quality copy of the Database and to verify that the data contained therein have been selected on the basis of sound scientific judgment. However, NIST makes no warranties to that effect, and NIST shall not be liable for any damage that may result from errors or omissions in the Database ...
Ihnat, Peter M.; Vennerstrom, Jonathan L.; Robinson, Dennis H., Synthesis and solution properties of deferoxamine amides, J. ...
Deferoxamine - Last updated on January 20, 2020. ©2020 Memorial Sloan Kettering Cancer Center. ... If you have an allergy to deferoxamine or any other part of this drug. ...
Deferoxamine may cause some people to have hearing and vision problems within a few weeks after they start using it. This ...
Deferoxamine - An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and causing cancer cell death ... Medical Word - Deferoxamine. Ans : An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and ... Deferoxamine - Glossary. Written & Compiled by Medindia Content Team. Medically Reviewed by The Medindia Medical Review Team on ...
Deferoxamine - Last updated on November 18, 2019. ©2019 Memorial Sloan Kettering Cancer Center. ...
Deferoxamine hydrochloride. G9VYJ96FOJ. 1950-39-6. KCRQZLMAZHZDCL-UHFFFAOYSA-N. Deferoxamine mesylate. V9TKO7EO6K. 138-14-7. ... 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating ... Pms-Deferoxamine 500 mg/vial. 8.44USD vial. DrugBank does not sell nor buy drugs. Pricing information is supplied for ... Deferoxamine, otherwise known as desferrioxamine or desferal, is a chelating agent used to remove excess iron or aluminum from ...
Deferoxamine, used to treat iron overload, can be used to prevent leukemia cells from overtaking stem cell sites in the bone ... Addition of a drug used to treat iron overload, deferoxamine, improved the efficiency of chemotherapy in patients with an ... Understanding if deferoxamine is an option for treating AML in humans should take less than 5 years, compared to 10 to 15 years ... Deferoxamine has also been used to treat myelodysplasia, a leukemia-related disease where young blood stem cells do not mature ...
... Learn about reported side effects, ... DEFEROXAMINE (dee fer OX a meen) helps to remove excess iron from the body. This may be necessary in patients who have received ...
Deferoxamine for the Treatment of Hemochromatosis. The safety and scientific validity of this study is the responsibility of ... Deferoxamine (Desferal) is a drug that binds to iron and allows it to be excreted from the body. It is the only effective way ... Deferoxamine, when given by the subcutaneous route, has been shown to reduce substantially the total iron burden in thalassemic ... To determine if deferoxamine, given regularly, can indefinitely prevent the heart, liver, and endocrine complications ...
Experimental: Deferoxamine Mesylate Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive ... Deferoxamine Mesylate in Intracerebral Hemorrhage Investigators. Safety and tolerability of deferoxamine mesylate in patients ... Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial. The safety and scientific validity of this study is the ... Drug: Deferoxamine Mesylate Placebo Comparator: Normal Saline Normal saline (0.9% sodium chloride) given by intravenous ...
Deferoxamine / Placebo Peak plasma concentration (Cmax). *Pharmacokinetics (blood) [ Time Frame: 12 weeks ]. Deferoxamine / ... Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment (D-SCOUT). The safety and scientific validity of this study is the ... Safety will be assessed based upon known adverse outcomes of Deferoxamine (DFO) therapy. Skin will be examined for evidence of ... Deferoxamine. Siderophores. Iron Chelating Agents. Chelating Agents. Sequestering Agents. Molecular Mechanisms of ...
Deferoxamine for ,=2 weeks prior to stem cells. Drug: deferoxamine Given intravenously or subcutaneously over 8-12 hours daily ... Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation. The safety and scientific validity of this study is ... Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. [ Time Frame: ... In this study we are examining the use of deferoxamine starting 2 weeks to 3 months prior to transplantation and continuing ...
Intranasally administered deferoxamine (DFO) is being developed by our laboratory for the treatment of several ... Detection of deferoxamine using liquid chromatography/mass spectrometry with electrospray ionization [poster] Conference Poster ...
Also Known As: Desferal; Desferrioxamine; Deferoxamine B; Deferoxamine Mesilate; Deferoxamine Mesylate Show All ,, Networked: ... Deferoxamine (Desferal) Summary Description: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is ... Key Diseases for which Deferoxamine is Relevant. * Iron Overload : 36 outcomes 37 studies in 393 results ...
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, ... Desferal; Desferrioxamine; Deferoxamine B; Deferoxamine Mesilate; Deferoxamine Mesylate; Deferoxamine Methanesulfonate; ... Deferoxamine; Mesylate, Deferoxamine; Mesylate, Desferrioxamine B; Methanesulfonate, Deferoxamine; Butanediamide, N-(5-((4-((5 ... Deferoxamine (Desferal). Subscribe to New Research on Deferoxamine Natural product isolated from Streptomyces pilosus. It forms ...
Buy Deferoxamine for peak identification CRS 1 online at LGC Standards, high-quality reference standards for pharmaceutical ...
Abstract Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the ... Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats. Hao J1, Li B1, ... Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism ... Mechanisms underlying the promotion of functional recovery by deferoxamine Neural Regen Res. 2017 Jun;12(6):959-968. Mechanisms ...
The objective of this research study is to determine the safety and feasibility of chelation therapy with deferoxamine for ... Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. ... All patients who received chelation therapy were monitored for grade 3 or above toxicity Attributable to Deferoxamine(grades ... A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With ...
where to buy 138-14-7(Deferoxamine mesylate).Also offer free database of 138-14-7(Deferoxamine mesylate) including MSDS sheet( ... Deferoxamine mesilate (JP14);Desferal;Prestwick_988;Deferoxamine mesylate (USP);Butanediamide,N-[5-[[4-[[5-(acetylhydroxyamino ... Deferoxamine Mesylate supplierAppearance:White to off-white powder Storage:Keep away of light,cool place Package:25kg/drum; ... Product Name: DEFEROXAMINE MESYLATE Synonyms: Desferioxamine mesylate;N4-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino-1,4- ...
The authors results suggest that the administration of deferoxamine may have the potential for clinical tran … ... and a threefold increase in the rate of union with the use of deferoxamine. ... The irradiated fracture plus deferoxamine group received injections of deferoxamine into the fracture callus after surgery. ... Deferoxamine restores callus size, mineralization, and mechanical strength in fracture healing after radiotherapy Plast ...
The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats.. Saad SY1, ... The iron chelating activity of deferoxamine (DFO) has been exploited to obtain protection against the peroxidative damage in ...
Cardiovascular Disease (CVD) Terminated Phase 2 Trials for Deferoxamine (DB00746). Back to Cardiovascular Disease (CVD) ...
The average value (mean ± SEM) for the urinary iron/24 h for all patients with 3 g deferoxamine/24 h was 44.52 ± 20.20 mg.. ... Figure 1. Effect of intravenous deferoxamine dose on thalassemic patients. Each line corresponds to the mean excretion rate of ... Figure 2. Increase of urinary iron excretion induced by 6 and 9 g/day of intravenous deferoxamine in relation to the excretion ... Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal ...
No known allergy or contraindication to the administration of deferoxamine. - Ability to comply with all study-related ... 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood ... 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood ...
Deferoxamine (DFO/Desferal®) to accelerate bone healing and treat fracture healing disorders (PROOF-DESFERAL). 03/2021-02/2024 ... In the proposed study, we aim at paving the path for using the HIF-stabilizer Deferoxamine (DFO) for a new application to ...
Buy Deferoxamine mesylate (CAS 138-14-7), an iron chelator which induces apoptosis, from Santa Cruz. Purity: ≥97%, MF: ... Deferoxamine mesylate (CAS 138-14-7) Deferoxamine mesylate , CAS 138-14-7 is rated 5.0 out of 5 by 1. ... Deferoxamine mesylate Product Citations See how others have used Deferoxamine mesylate. Click on the entry to view the PubMed ... Deferoxamine Mesylate is an inhibitor of Prolyl Hydroxylase.. References. 1. Porreca, E., et al. 1994. Arterioscler. Thromb. 14 ...
M deferoxamine (DFO) at 48 hours. The means ± SDs for all seven patients (a-g) are shown in (h) (Wilcoxon matched pairs test). ... M deferoxamine (DFO) at 48 hours. The means ± SDs for all seven patients (a-g) are shown in (h) (Wilcoxon matched pairs test). ... L. Jiang, W. W. Peng, L. F. Li et al., "Effects of deferoxamine on the repair ability of dental pulp cells in vitro," Journal ... Figure 2: Deferoxamine (DFO) inhibition of type II collagen cleavage by collagenase in human osteoarthritic (OA) articular ...
Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion. You will receive an email whenever this ... PURPOSE: Although toxic to the retina in its native form, the iron chelator deferoxamine (DFO) shows no apparent retinal ... P Gehlbach, R L Purple; Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion.. Invest. ...
  • Deferoxamine (DFOA), also known as desferrioxamine and sold under the brand name Desferal, is a medication that binds iron and aluminium. (wikipedia.org)
  • Deferoxamine (Desferal) is a drug that binds to iron and allows it to be excreted from the body. (clinicaltrials.gov)
  • Desferal (deferoxamine) is a member of the antidotes drug class and is commonly used for Iron Poisoning - Acute, and Iron Poisoning - Chronic. (drugs.com)
  • A generic version of Desferal is available, see deferoxamine prices . (drugs.com)
  • The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. (clinicaltrials.gov)
  • The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage. (clinicaltrials.gov)
  • Subjects will be randomized to either deferoxamine mesylate (DFO) at 32 mg/kg/day (up to a maximum daily dose of 6000 mg/day), or saline placebo, given by IV infusion for 3 consecutive days. (clinicaltrials.gov)
  • Deferoxamine Mesylate, an iron chelator, has been found to inhibit thymidine incorporation in cell cultures which is antagonized by iron supplementation. (scbt.com)
  • Additionally, Deferoxamine Mesylate demonstrates the ability to induce p53 and cell accumulation in the G1 phase of cell growth and increase p21 mRNA levels without any detectable protein products. (scbt.com)
  • Deferoxamine Mesylate is an inhibitor of Prolyl Hydroxylase. (scbt.com)
  • See how others have used Deferoxamine mesylate. (scbt.com)
  • How long can Deferoxamine mesylate be stored for? (scbt.com)
  • Thank you for asking about our product Deferoxamine mesylate (CAS# 138-14-7). (scbt.com)
  • NDA 076806 describes DEFEROXAMINE MESYLATE , which is a drug marketed by Fresenius Kabi Usa , Gland Pharma Ltd , Hospira , Watson Labs , and West-ward Pharms Int , and is included in five NDAs. (drugpatentwatch.com)
  • Additional details are available on the DEFEROXAMINE MESYLATE profile page. (drugpatentwatch.com)
  • The generic ingredient in DEFEROXAMINE MESYLATE is deferoxamine mesylate . (drugpatentwatch.com)
  • Did the author experience muscle spasms while taking deferoxamine mesylate ? (druginformer.com)
  • This study reports the effects of the iron chelator deferoxamine (DFO) on collagen cleavage, inflammation, and chondrocyte hypertrophy in relation to energy metabolism-related gene expression in osteoarthritic (OA) articular cartilage. (hindawi.com)
  • PURPOSE: Although toxic to the retina in its native form, the iron chelator deferoxamine (DFO) shows no apparent retinal toxicity when bound to hydroxyethyl-starch (HES). (arvojournals.org)
  • Our aim was to test the association of NAC and an iron chelator (deferoxamine - DFX) on cardiac remodeling in a rodent model of AMI. (ahajournals.org)
  • Using cardiac T2* as a primary endpoint, we will investigate whether the oral chelator, deferiprone in combination with traditional treatment (deferoxamine), is superior in removing cardiac iron as compared to deferoxamine alone. (ichgcp.net)
  • Deferoxamine administration, an iron chelator, offers a neuroprotective action in ischemia/reperfusion animal models. (strokecenter.org)
  • Treatment of monocytes with deferoxamine, an iron chelator, suppressed the survival of yeasts in a concentration-dependent manner. (unesp.br)
  • The iron chelator deferoxamine induced both HIF-1alpha and p53, but p53 up-regulation could still be detected in HIF-1alpha-deficient cells, suggesting that mechanisms other than HIF-1alpha activation contribute to oxygen-regulated p53 induction. (nih.gov)
  • Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo: An oxidative stress based apoptosis, physicochemical and neurological study profile. (edu.qa)
  • Starch-Deferoxamine (S-DFO), a novel high molecular weight iron chelator, was produced to increase binding capacity to iron and reduce toxicity. (edu.qa)
  • Finally, we show that intra-ventricular delivery of the iron chelator deferoxamine results in an improvement of the motor phenotype in R6/2 HD mice. (ccpl.org)
  • Apart from iron toxicity, deferoxamine can be used to treat aluminium toxicity (an excess of aluminium in the body) in select patients. (wikipedia.org)
  • All patients who received chelation therapy were monitored for grade 3 or above toxicity Attributable to Deferoxamine(grades defined by the CTCAE Version 3). (clinicaltrials.gov)
  • The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. (nih.gov)
  • Ascorbic acid may ↑ effectiveness of deferoxamine but may also ↑ cardiac iron toxicity. (thefreedictionary.com)
  • Effect of deferoxamine and sympathectomy. (cumhuriyet.edu.tr)
  • To elucidate whether the pro-osteogenic effect of deferoxamine is mediated via Wnt signaling, we performed a Wnt profiler array of deferoxamine-treated osteoblasts. (haematologica.org)
  • The promoting effect of deferoxamine on matrix mineralization in wild-type cells was completely abolished in Wnt5a −/− cells. (haematologica.org)
  • By simulating ischemia/reperfusion on rats we demonstrated the positive effect of deferoxamine on iron metabolism parameters (higher levels of transferrin, less ferritin and free iron, which received the drug group), also observed a decrease in the concentration of von Willebrand factor, as a measure of endothelial dysfunction. (intensive-care.ru)
  • Thus, we can conclude about the positive effect of deferoxamine on the parameters of iron metabolism, microcirculation and blood rheologyin critical conditions involving ischemia/ reperfusion. (intensive-care.ru)
  • The effect of deferoxamine was reversed by iron-saturated transferrin (holotransferrin) but not by nonsaturated transferrin (apotransferrin). (unesp.br)
  • Chronic use of deferoxamine may increase the risk of hearing loss in patients with thalassemia major. (wikipedia.org)
  • Deferoxamine therapy in lifelong transfusion-dependent anaemias, as beta-thalassemia major, is associated with an increased risk of ototoxic changes. (uniss.it)
  • Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. (ucl.ac.uk)
  • A 34-year-old man with thalassemia major complained of nyctalopia and decreased vision following high-dose intravenous deferoxamine to treat systemic iron overload. (biomedcentral.com)
  • A 34-year-old Taiwanese man with beta-thalassemia major had been administered routine blood transfusion and subcutaneous deferoxamine at 30 mg/kg/day for 20 years since youth. (biomedcentral.com)
  • Iron overload was evaluated for 26 ß-thalassemia homozygous patients, and 14 of them were submitted to intensive chelation therapy with high doses of intravenous deferoxamine (DF). (scielo.br)
  • The physico-chemical solution properties of deferoxamine were modified by acylating the terminal amino group with short-chain aliphatic, succinic, and methylsulphonic moieties. (nebraska.edu)
  • To describe the spectral domain optical coherence tomography (SD-OCT) findings of a patient who developed pigmentary retinopathy following high-dose deferoxamine administration. (biomedcentral.com)
  • He presented with acute onset of decreased vision, impaired color vision, and night blindness following continuous intravenous deferoxamine (98 mg/kg) for 42 days for the treatment of elevated serum ferritin level. (biomedcentral.com)
  • Previous animal studies have explored the therapeutic effects of deferoxamine (DFX) via its iron-chelating properties after SAH, but none have assessed the necessity of microglial/macrophage heme oxygenase-1 (HO-1 or Hmox1) in DFX neuroprotection, nor has the efficacy of an intracerebroventricular (ICV) administration route been fully examined. (biomedcentral.com)
  • Common side effects of deferoxamine include injection site pain, rash, and fever. (rxwiki.com)
  • Iron Accumulates in Huntington's Disease Neurons: Protection by Deferoxamine. (ccpl.org)
  • These findings, together with protection by deferoxamine, support a potentiating role of neuronal iron accumulation in HD. (ccpl.org)
  • Since combining deferiprone and deferoxamine has an additive effect, placing all patients into net negative iron balance, we investigated the possibility that combining deferasirox and deferoxamine would lead to similar results. (haematologica.org)
  • abstract = "A 49-year-old woman undergoing long-term hemodialysis and treated with deferoxamine (DFO) 1.5 g twice weekly for aluminum bone disease developed fever and bilateral calf pain caused by myonecrosis with gas gangrene. (elsevier.com)
  • The objective of this research study is to determine the safety and feasibility of chelation therapy with deferoxamine for patients with iron overload who are receiving a stem cell transplant. (clinicaltrials.gov)
  • ferritin ≥ 1000 ng/ml and liver iron content(LIC) ≥ 5 mg/gdw were enrolled and received chelation therapy with Deferoxamine. (clinicaltrials.gov)
  • All patients meeting the criteria for Severe iron overload as defined by BOTH: ferritin ≥ 1000 ng/ml and liver iron content(LIC) ≥ 5 mg/gdw were enrolled and received chelation therapy with Deferoxamine. (knowcancer.com)
  • We conclude that supplementing the daily use of deferasirox with 2 - 3 days of deferoxamine therapy would place all patients into net negative iron balance thereby providing a convenient way to tailor chelation therapy to the individual needs of each patient. (haematologica.org)
  • If a patient has an elevated ferritin level, chelation therapy with deferoxamine or deferasirox should be considered. (medscape.com)
  • Deferoxamine can be used for chelation therapy. (medscape.com)
  • Deferoxamine is a siderophore from the bacteria Streptomyces pilosus. (wikipedia.org)
  • Deferoxamine, a siderophore produced by Streptomyces pilosus ( 14 ), is the standard iron chelation agent used for the treatment of patients with iron overload. (asm.org)
  • This study was undertaken to test whether a bacterial siderophore, deferoxamine (DFO), could trigger inflammatory signals in human intestinal epithelial cells as a single stimulus. (jimmunol.org)
  • Treatment with iron-chelating drugs such as deferoxamine reduces mortality in persons with sickle cell disease or β‐thalassemia who are transfusion dependent. (wikipedia.org)
  • Some patients fail to respond adequately to deferoxamine and deferasirox monotherapy while others have side effects which limit their use of these drugs. (haematologica.org)
  • Deferoxamine belongs to a group of drugs called iron chelators. (rxwiki.com)
  • If you have an allergy to deferoxamine or any other part of this drug. (mskcc.org)
  • Deferoxamine, a drug used to treat iron overload, blocks leukemia cells from invading stem cell areas in the bone marrow. (medindia.net)
  • Addition of a drug used to treat iron overload, deferoxamine , improved the efficiency of chemotherapy in patients with an aggressive type of leukemia called acute myeloid leukemia (AML). (medindia.net)
  • Understanding if deferoxamine is an option for treating AML in humans should take less than 5 years, compared to 10 to 15 years for an entirely new drug. (medindia.net)
  • Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism for this action remains unknown. (rutgers.edu)
  • Deferoxamine, a drug used to treat patients with iron overload, has the capacity to promote systemic Y. enterocolitica infections in humans. (asm.org)
  • This trial tests whether the combination of traditional therapy (deferoxamine) with a newer drug (deferiprone) will prove more effective in removing cardiac iron than deferoxamine alone. (ichgcp.net)
  • Alles bij elkaar genomen, met betrekking tot de voordelige eigenschappen van de ontwikkelde sensor als een gebruiksvriendelijke, niet-giftige, wegwerpbare, kosteneffectieve en draagbare testkit, samen met die van smartphone-gebaseerde detectie, wordt verwacht dat dit detecterende bioplatform, die we lab-on-nanopapier noemen, zal bruikbaar zijn voor gevoelige, selectieve en gemakkelijke diagnose van ijzergerelateerde ziekten (ijzerdeficiëntie en ijzerstapeling) en therapeutische drug monitoring (TDM) van ijzerchelerende geneesmiddelen ook in klinische analyse. (orphiz.be)
  • Meghdad Payab, Mohammad Javad Chaichi, Ome Leila Nazari, Fatemeh Yousefnejad Maleki, Tannin Extraction from Oak Gall and Evaluation of Anti-Oxidant Activity and Tannin Iron Chelation Compared with Deferoxamine Drug, Journal of Drug Design and Medicinal Chemistry . (jddmc.org)
  • The present study aimed to determine the hearing status of patients with major thalassemia and its relationship with serum ferritin level, period of blood transfusion and deferoxamine administration . (bvsalud.org)
  • We examined the effects of subarachnoid hemorrhage (SAH) and treatment with deferoxamine (DFO) or sympathectomy on vascular smooth muscle function, as well as the underlying mechanisms involved, by recording the responses to noradrenaline and serotonin in isolated carotid arteries in vitro, All studies were performed before and 7 days after SAH. (cumhuriyet.edu.tr)
  • Alternative adaptation-related protection may also be inducible through the increased activity of hypoxia-inducible factors activated by hypoxia mimics such as iron chelation with deferoxamine (DFA). (elsevier.com)
  • The deferoxamine‐treated group experienced a reduction in their serum ferritin level to 226 ± 73 ng ml‐1 as a result of the deferoxamine treatment. (deepdyve.com)
  • Two of the deferoxamine‐treated patients were treated only once, two were treated twice, seven were treated three times and two were treated four times to achieve a ferritin level below 250 ng ml‐1. (deepdyve.com)
  • Long and worldwide experience has proven the efficiency of prophylaxis of iron overload based on the subcutaneous infusion of deferoxamine (DF) combined with oral vitamin C (1,4,6). (scielo.br)
  • Deferoxamine is usually administered as a slow, subcutaneous infusion through a portable pump. (medscape.com)
  • Deferoxamine is most effective when it is administered as a continuous infusion. (medscape.com)
  • Deferoxamine may be administered by intramuscular (IM) injection, slow infusion, SC bolus, or continuous infusion. (medscape.com)
  • We conducted 34-day metabolic iron balance studies in six patients in whom the relative effectiveness of deferasirox (30 mg/kg/day) and deferoxamine (40 mg/kg/day) was compared, alone and in combination. (haematologica.org)
  • All patients were in negative iron balance when treated with deferoxamine alone while four of six patients remained in positive balance when deferasirox monotherapy was evaluated. (haematologica.org)
  • Deferasirox is preferred because it is orally administered, whereas deferoxamine is administered intravenously (IV) or subcutaneously (SC). (medscape.com)
  • The fundus examination revealed multiple discrete hypo-pigmented circular lesions over the posterior pole and mid-peripheral retina in both eyes.Deferoxamine retinopathy was suspected, and the patient was switched to oral deferasirox/deferiprone. (biomedcentral.com)
  • Only recently data from combination of Deferasirox/Deferoxamine (DFX/DFO) have been reported showing that it can be safe and efficacious to remove iron overload, particularly in patients who do not respond adequately to a single chelating agent. (echosensclinicallibrary.com)
  • Deferoxamine is also used to minimize doxorubicin's cardiotoxic side effects and in the treatment of a patient with aceruloplasminemia. (wikipedia.org)
  • Deferoxamine is being studied as a treatment for spinal cord injury and intracerebral hemorrhage. (wikipedia.org)
  • Adding deferoxamine to chemotherapy treatment for Acute Myeloid Leukaemia (AML) increases survival prospects. (medindia.net)
  • Researchers plan to continue studying patients receiving deferoxamine as treatment for the prevention of heart complications associated with repeated blood transfusions. (clinicaltrials.gov)
  • To determine whether heart disease caused by transfusional hemochromatosis can be reversed by intensive treatment with deferoxamine. (clinicaltrials.gov)
  • Intranasally administered deferoxamine (DFO) is being developed by our laboratory for the treatment of several neurodegenerative diseases. (healthpartners.com)
  • The use of deferoxamine infusions to enhance the response rate to interferon‐α treatment of. (deepdyve.com)
  • Its discovery was a serendipitous result of research conducted by scientists at Ciba in collaboration with scientists at the Swiss Federal Institute of Technology in Zurich and the University Hospital in Freiburg, Germany Deferoxamine acts by binding free iron in the bloodstream and enhancing its elimination in the urine. (wikipedia.org)
  • Deferoxamine is excreted in urine and bile and discolors the urine red. (medscape.com)
  • Het huidige werk beschrijft de ontwikkeling van een "op nanopapier gebaseerd analytisch apparaat (NAD)", door het inbedden van curcumine in transparant bacterieel cellulose (BC) nanopapier, als een colorimetrische testkit voor het monitoren van ijzer en deferoxamine (DFO) als ijzer- chelaatvormer in biologische vloeistoffen zoals serumbloed, urine en speeksel. (orphiz.be)
  • Deferoxamine retinopathy primarily targets the RPE-Bruch membrane-photoreceptor complex, extending from the peri-fovea to the peripheral retina with foveola sparing. (biomedcentral.com)
  • This case report pathologically characterizes the spectral domain optical coherence tomography (SD-OCT, SPECTRALIS SD-OCT, Heidelberg, Germany) and near-infrared reflectance (NIR) findings in a patient with deferoxamine retinopathy. (biomedcentral.com)
  • Administration of ascorbate and deferoxamine reduces mortality and decreases lung injury through reduction of alveolar-capillary permeability, inflammation, and epithelial sloughing and lipid peroxidation. (pubmedcentralcanada.ca)
  • Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion. (arvojournals.org)
  • Previous studies have lead researchers to believe that deferoxamine, when given as an injection under the skin (subcutaneous), can be delay or prevent heart complications. (clinicaltrials.gov)
  • Our studies show that administration of ascorbate and deferoxamine reduced mortality and decreased lung injury through reduction of alveolar-capillary permeability, inflammation, and epithelial sloughing and lipid peroxidation. (pubmedcentralcanada.ca)
  • In a mouse experimental model of infection, the 50% lethal dose (LD 50 ) of strain IP864 was decreased by more than 5 log units in mice pretreated with deferoxamine, while a deferiprone pretreatment did not affect it. (asm.org)
  • Deferoxamine is produced by removal of the trivalent iron moiety from ferrioxamine B, an iron-bearing sideramine produced by the actinomycetes, Streptomyces pilosus. (wikipedia.org)
  • De reactie van GABA-aminotransferase verkregen uit Streptomyces decoyicus NBRC 13977 werd gecombineerd met die van het eerder ontwikkelde glutamaattestsysteem met behulp van glutamaatoxidase en peroxidase. (orphiz.be)
  • Deferoxamine effects on Plasmodium falciparum gene expression" by Ann M. Moormann, Paul A. Hossler et al. (umassmed.edu)
  • and Meshnick, Steven R., "Deferoxamine effects on Plasmodium falciparum gene expression" (1999). (umassmed.edu)
  • Exposure of the cells to iron dose-dependently attenuated osteoblast differentiation in terms of mineralization and osteogenic gene expression, whereas iron chelation with deferoxamine promoted osteogenic differentiation in a time- and dose-dependent manner up to 3-fold. (haematologica.org)
  • Chronic use of deferoxamine may cause ocular symptoms, growth retardation, local reactions and allergy. (wikipedia.org)
  • Does deferoxamine (DFX) alleviate posthemorrhagic chronic hydrocephalus (PHCH) by chelation of iron and suppression of the Wnt1/Wnt3a cellular pathway? (surgicalneurologyint.com)
  • During the chronic stage of vasospasm following SAH deferoxamine (DFO) was given to the animals and cervical and periarterial sympathectomy was performed in the other groups of animals. (cumhuriyet.edu.tr)
  • DEFEROXAMINE (dee fer OX a meen) helps to remove excess iron from the body. (cvs.com)
  • Deferoxamine is used to remove excess iron from the body. (rxwiki.com)
  • Approximately 60 subjects will be enrolled into this double-blind, placebo-controlled study for the Deferoxamine Intradermal Delivery Patch (DIDP). (clinicaltrials.gov)
  • These results suggest that deferoxamine decreases total iron ion, tumor necrosis factor-α, interleukin-1β, and caspase-3 expression levels after spinal cord injury and inhibits apoptosis and glial scar formation to promote motor function recovery. (rutgers.edu)